14 juillet 2022 – The European Medical Agency (EMA) published the assessment report for Covid-19 vaccine Valneva. Valneva is a vaccine for protecting people aged between 18 and 50 years against coronavirus disease 2019. It is used for primary vaccination.

The European Medical Agency (EMA) also published the paediatric investigation plan for Valneva. The paediatric investigation plan is aimed at ensuring that the necessary data are obtained to support the authorisation of a medicine for children, through studies in children.

For more information, see here and here.